Max Cani (@Max_Cani) header
Max Cani (@Max_Cani) profile picture

Max Cani

@Max_Cani

Medical Oncologist. Research Fellow at @GustaveRoussy

 Parigi, Francia
Joined September 2013
  • Tweets200
  • Following332
  • Followers257
41Media
Photo by Max Cani (@Max_Cani)Photo by Max Cani (@Max_Cani)Photo by Max Cani (@Max_Cani)Photo by Max Cani (@Max_Cani)Photo by Max Cani (@Max_Cani)Photo by Max Cani (@Max_Cani)Photo by Max Cani (@Max_Cani)Photo by Max Cani (@Max_Cani)Photo by Max Cani (@Max_Cani)Photo by Max Cani (@Max_Cani)
Such a huge work! Thanks to @mihaela_aldea @dani_mili7 @AriMarinel for all the efforts to arrive at this point! Happy for having contributed #RET #NSCLC #lungcancer
Clinical Cancer Research (@CCR_AACR) profile pictureClinical Cancer Research@CCR_AACROct 15
Now online: Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry doi.org/10.1158/1078-0432.CC…
Image from Clinical Cancer Research (@CCR_AACR)
2
155
Happy to have contributed to the ESMO Handbook of #Cancer #Prevention with the chapter “Lung Cancer Prevention: Public Health and Individual Approaches” Thanks to the Editors and the whole team!
ESMO - Eur. Oncology (@myESMO) profile pictureESMO - Eur. Oncology
@myESMOOct 7
👉 New for ESMO members! The ESMO Handbook of Cancer Prevention provides you with up-to-date evidence and global standards for primary, secondary and tertiary prevention. 🔗 Download the book now! ow.ly/w5xp50ZUwfF #ESMOBooks
3
59
From #WCLC26 We presented our data on cytisine for tobacco cessation in adults >65 yo: one of the largest cohorts in this setting. Cytisine resulted effective and safe, supporting its use also among older adults. Long-term FU is ongoing! A big thanks to the #RISP team!
Image from Max Cani (@Max_Cani)
1
2
100
Max Cani retweeted
Jordi Remon (@JordiRemon) profile picture
Jordi Remon@JordiRemonSep 7
Treatment landscape of early-stage NSCLC is evolving very fast. We review current SoC with IO and targeted therapies(TT) and future challenges: -Neoadj vs periop? -IO in borderline resectable -How to ⬆️pCR -Role of TT.. @peters_solange @g_mountzios authors.elsevier.com/sd/arti…
Image from Jordi Remon (@JordiRemon)
Image from Jordi Remon (@JordiRemon)
Image from Jordi Remon (@JordiRemon)
Image from Jordi Remon (@JordiRemon)
7
43
2
129
8,099
Advances in #lung #cancer treatment are defining new needs in the context of #survivorship. In this review, we explore the domains of lung cancer survivorship discussing how to address these emerging challenges. Many thanks to this multidisciplinary team! mdpi.com/2072-6694/18/17/285…
Image from Max Cani (@Max_Cani)
Image from Max Cani (@Max_Cani)
2
138
Now online on @JTOonline Smoking cessation is essential in lung cancer screening. In our study, with nearly 3,000 participants, cytisine achieved a 50.1% quit rate (vs 8.1% of counseling alone) with only mild side effects. A step forward for the field. sciencedirect.com/science/ar…
3
5
255
One of those puzzle pieces you don’t know exactly where to place 👇🏽
Annals of Oncology (@Annals_Oncology) profile pictureAnnals of Oncology@Annals_OncologyMar 3
🆕article in press: Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD doi.org/10.1016/j.annonc.202…
Image from Annals of Oncology (@Annals_Oncology)
1
2
4
920
Thanks for sharing! We hope similar efforts may improve awareness on this topic. Thanks to all co-authors. Great group!
Cecilia Pompili MD PhD FACS (@pompili_cecilia) profile pictureCecilia Pompili MD PhD FACS@pompili_ceciliaJan 5
Lung cancer in women is not just a biological disease. it’s shaped by delayed diagnosis, inequitable access, and unheard patient voices. We need data that truly reflect women’s experiences Great new review on #LungCancer in Women lungcancerjournal.info/artic… #lcsm
Image from Cecilia Pompili MD PhD FACS (@pompili_cecilia)
Image from Cecilia Pompili MD PhD FACS (@pompili_cecilia)
2
104
In our international multicenter cohort, 119 patients showed primary resistance to 1L ICI in PD-L1 ≥50% NSCLC. In 2L, continuing ICI + chemo improved outcomes vs chemo alone (PFS2 12.3 vs 7.0; OS 21.8 vs 10.1). Full paper here @ESMO_Open : sciencedirect.com/science/ar…
Image from Andrea De Giglio, MD PhD (@doctordegio)
4
1
17
3,701
👇Here a brief talk on lung cancer screening in Italy within the RISP trial. . repubblica.it/salute/dossier…
Tumore al polmone: la TAC a basso dosaggio salva vite. Ecco perché serve lo screening

Tumore al polmone: la TAC a basso dosaggio salva vite. Ecco perché serve lo screening

repubblica.it
1
46
Two intense days at the @AIOMtweet Congress. We discussed about liquid biopsy in early-stage NSCLC, and, during the plenary session, about the preliminary results of the RISP cost–benefit analysis (Italian lung cancer screening). Thanks to AIOM, to all RISP PIs and Pr. Novello.
Image from Max Cani (@Max_Cani)
6
130
At #ESMO25 we report a cost-effectiveness analysis of lung cancer screening in Italy (RISP program). Screening proves to be effective, and although preliminary, the data suggest a favorable cost-effectiveness profile. Updated results will be presented at the next #AIOM Congress!
Image from Max Cani (@Max_Cani)
7
501
Honored to present at the #ERS2025 congress the preliminary data on smoking cessation within the Italian lung cancer screening program. A great opportunity to exchange ideas on how to enhance and implement effective strategies in lung cancer screening.
Image from Max Cani (@Max_Cani)
4
185
Extremely glad to discuss with Prof. Volante the results of our group’s research “Comprehensive molecular analysis to depict signatures associated withTKI treatment response in advanced NSCLC and to identify novelpredictive biomarker” at the @thermofisher event. @unito
Image from Max Cani (@Max_Cani)
2
77
Thanks to IASLC for the great opportunity! Superb talks, strong engagement and inspiring enthusiasm among colleagues from all parts of the world. . @IASLC #WCLC25 #reviewerworkshop
Image from Max Cani (@Max_Cani)
3
102
It was an honor to present, on behalf of the co-investigators, the planned OS results from FLAURA2 ph III at #WCLC25. These results confirm a shift in our first-line practice for our EGFRm pts, marking the first time a study has achieved a significant benefit mOS of 4Y. #EGFR
Image from d.planchard (@dplanchard)
Image from d.planchard (@dplanchard)
Image from d.planchard (@dplanchard)
Image from d.planchard (@dplanchard)
5
46
2
186
13,286
Italian National Team at #WCLC2025 @AriMarinel @RobertoFerrara_ @Max_Cani @Gmazzaschi90 @pecci_federica1 @doctordegio @CarloGenova5 and many others 🇮🇹🍕
Image from Lodovica Zullo (@LodovicaZullo)
1
11
31
2,710
Don’t miss this excellent review on lung metastases. Congrats to @LodovicaZullo and the whole team! 👇🏽 nature.com/articles/s41572-0…
Lung metastases

Lung metastases

Nature Reviews Disease Primers - The lungs are a common metastatic site for several cancers, including colorectal cancer, primary lung cancer, breast cancer and prostate cancer. This Primer...

nature.com
5
85
Teamwork always pays off. Grateful to @AIOMtweet for the opportunity to share our insights on QoL in onc.-addicted NSCLC pts and their caregivers. More efforts should be directed toward addressing unmet needs i.e. self-coping, preservation of sexuality, and psychological support.
Image from Max Cani (@Max_Cani)
Image from Max Cani (@Max_Cani)
Image from Max Cani (@Max_Cani)
2
10
467
Bravo @Max_Cani for getting the "best poster" award for his work on Lung Cancer Screening in Italy 🇮🇹 #ELCC2025
Image from Lodovica Zullo (@LodovicaZullo)
1
1
8
750
Load more